NeoGenomics' Pharma Services offers Flow Cytometry Services including assays designed to detect and monitor Minimal Residual Disease (MRD) in hematologic cancers. Our newest platform (Becton Dickinson Fortessa X-20) and modular approach allow us to achieve the most clinically prognostic level of sensitivity using less sample than standard approaches because we can acquire up to 5 million events in a single tube. Our custom panels allow us to provide information on standard and exploratory markers to get the relevant information you want.
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